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(Genesis and/or GEDEFO) and health-economists (universities/public entities). 
The questionnaire consisted of 36 items with a Likert rating scale of 9 points (9 
= full agreement). Consensus was considered when more than two-thirds of the 
responses were in the same tercile. Results: A total of 101 experts where invited 
(40.6% oncologists; 44.6% hospital pharmacists and 14.8% health-economists). 
81% and 67% questionnaires were retrieved in the first and second round, respec-
tively. Only two rounds were required as variability was less than 10% (delta CV 
7.1%). Internal consistency of the questionnaire was high (α C: 0.886), as was the 
correlation between the rounds (R of Spearman: 0.946) Consensus was attained 
in 29 items. Most experts agreed on: i) the need to improve scales and quality 
of life-related measurements (96%, CI95%= 90.7-98.8%); ii) the need for Health 
Authorities to define a cost-effectiveness threshold (91%, CI95%= 84.5-97.9%) and 
if a different one for “end of life treatments” is required (81%, CI95%= 71.7-90.3%); 
iii) the importance of considering cost-effectiveness data along with the budget 
impact of oncologic therapies (97%, CI95%= 93.1-99,0%); iv) the need to consider 
the societal perspective in the assessment of advanced cancer treatments (94%, 
CI95%= 88.5-99.7%). Lack of consensus was observed regarding the use of mean or 
median overall survival as best efficacy variable for IO therapies ConClusions: 
Consensus in both clinical and pharmaco-economic aspects was high among the 
different health professionals. Lack of agreement in specific questions suggests 
the need for further research on these new therapeutic options.
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objeCtives: In patients with bone metastases from solid tumours, denosumab 
(Dmab) subcutaneous (SC) injection represents an alternative formulation to zole-
dronic acid (Zol) intravenous (IV) infusion with a superior efficacy for skeletal-related 
events prevention. This observational Time and Motion study estimated treatment 
duration endpoints associated with Dmab SC injection and Zol IV use as monother-
apy. Methods: In the ambulatory setting of 3 Belgian hospitals, patients with bone 
metastases from solid tumours were observed during administration of SC Dmab 
or Zol IV. The following pre-defined tasks were recorded in military time: patient 
registration, drug preparation, IV catheter installation (one site additionally included 
routine blood sampling), IV/SC drug administration (IV: infusion connection until 
disconnection; SC: syringe filling and injection), material disposal, and post-treatment 
monitoring. Active healthcare professional (HCP) time associated with aforemen-
tioned pre-defined tasks was recorded using a stopwatch. Time endpoints measured 
for each treatment were total task time, total active HCP time, drug administration 
duration, and patient chair time. Data (mean) were analyzed per site and pooled using 
a random intercept model. Results: 44 Dmab SC and 29 Zol IV observations were 
collected. Pooled data across sites showed a mean duration of Dmab SC injection of 
1.4 minutes (min) and 29 min for Zol IV (95% time reduction). The mean total tasks 
time was 10.3 min for SC Dmab and 49.2 min for IV Zol (-79%). When Dmab SC was 
used, active HCP time was decreased by 54% (6.5 min for SC Dmab vs. 14.2 min for 
Zol IV). Mean patient chair time was 12.2 min for SC Dmab and 60.5 min for IV Zol 
(-80%). ConClusions: Dmab SC injection was associated with time savings in all 
endpoints measured. Using SC Dmab administration instead of Zol infusion could 
improve patient comfort and free up hospital capacity to treat patients in Belgium.
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objeCtives: Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available 
as a superior treatment option in patients with bone metastases from solid tumours, 
compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. 
Although Zol was the mainstay treatment for skeletal-related events prevention, 
Dmab provides an alternative formulation to IV infusions. This Time and Motion 
study was conducted in Italy to estimate treatment duration endpoints associated 
with Dmab SC and Zol IV use. Methods: Patients with bone metastases from solid 
tumours scheduled to receive Dmab SC or Zol IV monotherapy in the outpatient 
setting of 5 Italian hospitals were included. The following pre-defined tasks were 
recorded in military time: patient registration, IV catheter installation, IV/SC drug 
administration (IV: infusion connection until disconnection; SC: syringe filling and 
injection), and post-treatment monitoring. Active healthcare professional (HCP) time 
was recorded using a stopwatch. Time endpoints were total task time, total active 
HCP time, drug administration duration, and patient chair time. Data (mean) were 
analysed per site and pooled by country using a random intercept model. Results: 
A total of 85 observations were collected (50 Dmab SC and 35 Zol IV). Across sites, 
mean administration duration of Dmab SC was 3.4 minutes (min) and 15.9 min for 
Zol IV (-78%). The mean total task time was 9.9 min for Dmab SC and 31.2 min for Zol 
IV (-68%). Time savings associated with Dmab SC versus Zol IV were also reflected 
in the total active HCP time (7.2 min vs. 12.1 min, -41%) and patient chair time (8.1 
perception was highly modified by a number of factors, most significantly order of 
presentation of risks and benefits and comprehension of a drug’s risks and benefits. 
Showing the favourable effects first could halve the odds ratio of a more nega-
tive score, with all other factors held constant. Better comprehension always led 
to more positive perception. Other significant factors included negative mood at 
time of answering and number of other formats already shown, both leading to 
more negative answers. Impact of presentation type was highly dependent on the 
therapeutic area. ConClusions: The perception of a drug’s benefit-risk can be 
heavily impacted by how it is presented to the patient. These results underline the 
importance of using an understandable presentation format in the communication 
of benefits and risks of drugs in order to support patients to make informed deci-
sions regarding their treatment choice.
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objeCtives: Between 10 and 29% of lung cancer (LC) are supposed to be attribut-
able to occupational exposures. However, LC of occupational origin remains under-
reported. To improve the identification and compensation of occupational LC, we 
implemented at the Léon-Bérard Cancer Centre, a questionnaire-based process to 
systematically identify LC patients potentially exposed at the workplace and to be 
seen in an “occupational cancer” consultation. Selection was based on patients’ 
reporting of exposure to carcinogens or potentially exposed occupations. The aim 
of this study was to assess the cost of this innovative program. Methods: The 
cost assessment was performed prospectively. Three situations were analyzed: 
questionnaire returned by the patient (up to one reminder), consultation required 
(situation 1), questionnaire returned (up to one reminder), no consultation 
required (situation 2), questionnaire not returned (up to one reminder) (situation 
3). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Data on consumption of resources were collected from 
the questionnaire administration until the physician evaluation and occupational 
cancer declaration if any. Uncertainty was captured by one-way and probabilistic 
sensitivity analyses using a non-parametric bootstrap method. All costs were 
given in 2014 euros. Results: 310 patients were enrolled from March 2014 to 
May 2015. 9 patients without lung cancer were excluded. The measured costs per 
patient were in average € 179 (SD: 53) for situation 1 (n= 77), 40€ (SD 16) for situation 
2 (n= 82), and € 24 (SD: 7) for situation 3 (n= 142). Sensitivity analyses showed that 
the unit costs of physician and duration of consultations had a major role in the 
process’ costs. ConClusions: The implementation of our approach increased the 
identification and the compensation of occupational lung cancer. Our approach 
responds to the objectives of the National Cancer Plan and helps to improve the 
overall care of patients with cancer.
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objeCtives: The number of patients seeking cancer information over the internet 
is increasing. However, it is unknown what kind of information sources is available 
online in Japan, UK and USA. The objective of the study is to evaluate the informa-
tion sources related to breast cancer and to compare the information source among 
Japan, UK and USA. Methods: We identified top-rated 20 information sites and 
the number of advertisements on the initial screen by using a key word as “Breast 
cancer” on Yahoo and Google sites in Japan, UK and USA. Information sources were 
defined and categorized into six kinds of information organizers; public institutes, 
academic associations, NGO/NPOs, information portal, advertisements, and corpo-
rate sponsored sites. The each information source was categorized by two evalu-
ators independently. Third evaluator reconciled and decided the category of the 
information source if evaluation results were not identical between two evaluators. 
The proportion of internet sources by six categories was calculated and compared 
among three countries. Results: In Japan, the proportion of information sources 
by public institutions and academic associations was 30%. Less than 10% of infor-
mation sources were by NGO/NPOs. More than half of information sources were 
advertisements. In UK, 70% of information sources were provided by NGO/NPOs 
whereas less than 20% of information sources were advertisement. In USA, 30% 
of information sources were by academic institutions whereas more than 50% of 
information sources were by information portal. ConClusions: This comparative 
survey provides an overview of information sources related to breast cancer avail-
able on the internet. The number of top-rated information sites by public institutes, 
academic associations was low compared to UK and USA. There were a few informa-
tion sources by NGO/NPO in Japan.
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objeCtives: Clinical and health-economic criteria to accurately assess the 
value of new immuno-oncology (IO) drugs are currently undetermined. The aim 
of this study was to assess the current knowledge about these criteria among 
the Spanish scientific community. Methods: The Delphi method was used to 
survey a multi-disciplinary group of Spanish oncologists [melanoma, lung, or 
genitourinary-specialists (hospital/regional managers)], hospital pharmacists 
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by the G-BA. Methods: Oncology medicines with completed EBAs by 01 Jan 2015 
were analysed for i) presence of cross-over in pivotal trials; ii) efficacy results before 
and after cross-over and iii) evidence levels granted by the G-BA (proof, indication 
or hint). Results: Cross-over was frequent in oncology, concerning 14 of 28 EBAs 
(50%). For 6 of the 14 medicines, cross-over could be considered ethically required as 
significant differences in overall survival (OS) were demonstrated prior to cross-over. 
For most medicines, data on OS and progression-free survival were reported after 
cross-over (10/14 and 8/14, respectively). Significant differences in OS post-cross-over 
could only be shown for 2 out of the 8 medicines for which no such differences were 
demonstrated before cross-over. An evidence level of proof was granted by the G-BA 
for 3 out of the 14 medicines, all of which were orphan drugs, but none were granted 
for medicines with ethically required cross-over. ConClusions: The G-BA regards 
evidence standards as only partially fulfilled in cases of ethically required cross-over 
in oncology. Highly efficacious drugs with ethically mandated cross-over are there-
fore systematically disadvantaged with regards to the achievable evidence category, 
indicating a bias against innovation. Medicines with a demonstration of superior effi-
cacy and subsequent ethically justified cross-over deserve an evidence level of proof.
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objeCtives: The need and price for cancer drugs will increase while budgets 
are becoming more constrained. Policy makers need to make hard choices about 
which drugs are worthwhile. Inclusion of societal preferences in resource alloca-
tion is emphasized by academic research and policy makers. This study qualita-
tively assesses societal preferences for market access of cancer drugs. Methods: 
Focus group discussions (FGD) with members of the general population in Flanders 
(Belgium) were organized. Participants were recruited through flyers distributed in the 
University Hospitals Leuven and social media. First, the topic of budgetary constraints 
and resource allocation was introduced. Next, introductory statements based on ethi-
cal principles were discussed. Hypothetical scenarios were set up to ask people about 
characteristics of a patient, disease and drug that they would use to prioritize if there 
is only money to use/treat one of them. FGD were led by one researcher, video and 
audio recorded, verbatim transcribed and analyzed using thematic framework analy-
sis. FGD were repeated until data saturation. Participants received a compensation 
of € 20. Results: Three FGD with each six participants were conducted in February 
2015. The median age of participants was 43 years (22-65, N= 18). When participants 
are asked to define criteria they would use to prioritize patients, they mention age and 
life style of a patient and severity of the disease. They prefer to treat the largest patient 
group with the best prognosis. Drugs would be prioritized by participants based on 
the effect on quality of life, side effects and treatment duration. ConClusions: 
Participants would like to maximize the benefits within a restricted budget, but con-
flicts between criteria such as prognosis and severity of disease crop up. Further 
research will quantify the relative importance and the trade-offs between criteria 
that society is willing to make through a discrete choice experiment.
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objeCtives: To understand the impact of supply chain and healthcare system struc-
ture on public price for oncologics in selected emerging markets. Methods: Review 
of published price data and publicly available information from health authorities, 
WHO websites, peer reviewed and scholarly publications. Primary input from current 
payers and healthcare for validation and gap mitigation. Results: In the selected 
countries, when comparing to the US pharmacy price as benchmark, oral targeted 
oncologics were priced lower than injectable oncologics. Brazil and the Mexican pri-
vate sector saw the largest disparity with difference of approximately 40% between 
orals and injectables. Taiwan had the smallest difference between orals and injecta-
bles with only a 4% difference. China had the highest prices among the selected 
countries. In countries with both a public and private market, the prices in the public 
sector were always lower than those in the private sector. The ex-factory prices in 
the selected countries were much closer, with maximum 16% difference between 
lowest to highest price level. Brazil has the highest ex-factory price for orals with 
72% and China has the highest for injectables with 77%. South Korea had the lowest 
ex-factory and pharmacy prices for both orals and injectables. ConClusions: The 
combination of no reimbursement, a regionalized approach to pricing, and a com-
plex distribution chain has led to highest mark-ups at pharmacy level price in China 
among the selected countries despite having similar ex-factory prices. Due to tougher 
price negotiations in the public sectors, targeted oncology products enter the Brazil 
and Mexico markets in the private sector first then enter the public market which 
allows for greater the average price differential between public and private sectors. 
With universal healthcare systems in South Korea and Taiwan and international price 
referencing the price differences between orals and injectables and the mark up from 
ex-factory to pharmacy purchasing price is negligible.
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objeCtives: Three target therapies for advance CRC had been approved by TFDA 
since 2005; only two are under reimbursement now. Long reimbursement process 
had prevented advanced CRC patients from prescribing target therapy. This study 
is to use Cetuximab, the first reimbursed target therapy to evaluate the impact of 
min vs. 23.3 min, -65%). ConClusions: Time savings associated with Dmab SC 
injection were seen for all outcome measures. Opting for Dmab SC injection instead 
of Zol IV infusion should free up the hospital capacity to treat more patients, and 
decrease patients’ treatment burden in Italy.
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objeCtives: The HIRE – Oncology contains clinical oncology data captured as part 
of the Cancer Care Quality Program (CCQP), a novel program by Anthem health 
plans designed to align reimbursement with evidence-based, cost-effective oncol-
ogy treatment, that is integrated with administrative claims data in the HealthCore 
Integrated Research Database (HIRD). This study updates prior research describing 
the baseline characteristics of patients within oncology practices participating in the 
CCQP. Methods: Breast, colon, and lung cancer patients from HIRE-Oncology were 
identified between 6/23/2014 and 3/6/2015 (Intake Period). Patients were character-
ized based on the earliest request to utilize chemotherapy and/or supportive care 
medications (Index Date) during the Intake Period; analyses included patients with ≥ 6 
months of continuous pre-index eligibility. Baseline characteristics were stratified by 
cancer type/stage and included: pathology, biomarkers, health care costs, and Deyo-
Charlson Index (DCI). Results: A total of 2,206 breast, 554 colon, and 796 lung cancer 
patients were identified with mean(SD) ages and DCI’s of 64(10), 56(10), and 61(9) and 
5.6(3.2), 7.6(2.6), and 7.8(2.8), respectively. Stage distributions indicated the greatest 
prevalence with stage IV disease: 36%, 73%, and 74% among breast, colon, and lung 
cancers patients. Pathology results among lung cancer patients demonstrated 78% 
and 22% with non-small cell and small cell cancers, respectively. 36% of breast cancer 
patients were HER2 positive, 34% of lung cancer patients were detected with EGFR 
mutation, and 32% of colon cancer patients were detected with KRAS mutation among 
those reporting test results. Across all stages, total all-cause mean (SD) baseline health 
care costs were $51,430($58,567), $67,760($59,064), and $59,789($55,846) among breast, 
colon, and lung cancer patients, respectively. ConClusions: This updated analysis 
provides valuable initial insight into the demographic and clinical characteristics of 
patients within participating practices during the first year. HIRE-Oncology provides 
a comprehensive picture for commercially-insured oncology patients and baseline 
data for future program evaluation.
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objeCtives: To assess physician support of the 2014 ASCO payment reform pro-
posal, focusing on four components: 1) new patient payments- single payment for 
any new patient until treatment begins; 2) treatment month payments-each month 
the patient is treated; 3) active monitoring month payments-during months when 
the patient is not actively treated but receiving care and support; 4) transition of 
treatment payments-for a change in patient status during a month. Methods: 
Medical-oncologists and hematologist/oncologists across the US, practicing for at 
least 2yrs and managing at least 20 patients, were randomly sampled to participate 
in a cross-sectional survey via a panel. Results: 231 physicians participated (87% 
physicians, 13% medical directors; 67.5% hematologist/oncologists, 32.5% medical-
oncologists). Mean practice duration:15yrs; 53% practice in an academic/community/
Veteran’s facility and 47% in group/solo private practice; geographic distribution: 
South:32%/Northeast:29%/Midwest:23%/West:17%. Only 7% rated the reimburse-
ment climate as “excellent” (good:32%/satisfactory:42%/not very good:20%/bad:2%); 
18% rated the financial status of their cancer program as “excellent” (good:41%/sat-
isfactory:33%/not very good:7%/bad:< 1%). Physicians reporting that they “strongly” 
or “somewhat” support the components of the 2014 ASCO proposal: 1) new patient 
payments:47%; 2) treatment month payments:57%; 3) active monitoring month pay-
ments:55%; and 4) transition of treatment payments:54%. Physician rating of “strong/
somewhat support” based on perception of reimbursement climate (excellent/good 
vs. satisfactory/not very good/bad): 1) new patient payments:55%/42%; 2) treatment 
month payments:66%/51%; 3) active monitoring month payments:65%/48%; 4) 
transition of treatment payments:61%/50%. “Strong/somewhat” support based on 
perception of financial status of their cancer program (excellent/good vs. satisfac-
tory/not very good/bad): 1) new patient payments:49%/44%; 2) treatment month 
payments:61%/52%; 3) active monitoring month payments:60%/47%; 4) transition of 
treatment payments:59%/47%. ConClusions: About half of the physicians in the 
study supported the components of ASCO’s 2014 proposed payment reform, espe-
cially if they already considered the current reimbursement climate and financial 
status of the cancer program to be positive.
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objeCtives: In Germany, an early benefit assessment (EBA) by the Federal Joint 
Committee (G-BA) is compulsory for all new drugs. Pre-defined treatment switching, 
often called ‘cross-over’, is often seen in oncology clinical trials. Cross-over is usu-
ally implemented for ethical reasons, i.e. to ensure access to a beneficial treatment 
for all patients, but may confound data analysis by improving efficacy in the con-
trol arms. We aimed to analyse the impact of cross-over on evidence levels granted 
